论文部分内容阅读
目的 :探讨重组干扰素α 1b(赛若金 )治疗慢性丙型肝炎的疗效及不良反应。方法 :选择慢性丙型肝炎患者 65例 ,随机分成治疗组 35例 ,给予赛若金治疗 ,第 1～ 4周 30 μg·d-1,im ;第 5～ 16周为隔日 30 μg ,im。对照组 30例 ,按常规给予降酶、退黄及护肝药物。结果 :2组ALT及SBIL均有显著下降 ,但治疗组疗效显著高于对照组 (P <0 .0 5 )。治疗组抗丙型肝炎病毒转阴率为 37.1% ,显著高于对照组 (3.3% ) (P <0 .0 5 ) ,未见严重的药物不良反应。结论 :赛若金治疗慢性丙型肝炎 ,安全有效 ,是一个值得临床推广的药物
Objective: To investigate the efficacy and adverse reactions of recombinant interferon alfa 1b in treating chronic hepatitis C patients. Methods: Sixty-five patients with chronic hepatitis C were randomly divided into treatment group (n = 35) and treated with race gold. The first to fourth weeks were 30 μg · d-1, im; the fifth to the 16th week were 30 μg every other day. The control group of 30 patients, according to conventional administration of Jiangni, Huang and liver protection drugs. Results: The ALT and SBIL in both groups decreased significantly, but the therapeutic effect in the treatment group was significantly higher than that in the control group (P <0.05). The negative rate of anti-hepatitis C virus in the treatment group was 37.1%, which was significantly higher than that in the control group (3.3%) (P <0.05). No serious adverse drug reactions were observed. Conclusion: Saurocofen is safe and effective in the treatment of chronic hepatitis C, which is worthy of clinical promotion